96027-84-8 Usage
Description
2-n-Butyl-4-[(2-Bromoethoxy)-3,5-diiodobenzoyl]benzofuran is a complex organic compound characterized by its light yellow solid appearance. It features a benzofuran core with a butyl group at the 2nd position and a substituted benzoyl moiety at the 4th position. The benzoyl group contains a 2-bromoethoxy side chain and two iodine atoms at the 3rd and 5th positions, which may contribute to its unique chemical properties and potential applications.
Uses
Used in Pharmaceutical Industry:
2-n-Butyl-4-[(2-Bromoethoxy)-3,5-diiodobenzoyl]benzofuran is used as a potential amiodarone metabolite in the pharmaceutical industry. Due to its significant structural similarity to thyroid hormone and its metabolites, the iodothyronamines, it may have implications in the development of treatments for thyroid-related conditions or in the study of thyroid hormone metabolism.
Used in Chemical Research:
As a light yellow solid with a unique structure, 2-n-Butyl-4-[(2-Bromoethoxy)-3,5-diiodobenzoyl]benzofuran can be utilized in chemical research for the investigation of its properties, reactivity, and potential interactions with other compounds. This may lead to the discovery of new applications or the enhancement of existing ones in various fields, including medicine, materials science, and environmental chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 96027-84-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,6,0,2 and 7 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 96027-84:
(7*9)+(6*6)+(5*0)+(4*2)+(3*7)+(2*8)+(1*4)=148
148 % 10 = 8
So 96027-84-8 is a valid CAS Registry Number.
InChI:InChI=1/C21H19BrI2O3/c1-2-3-7-18-19(14-6-4-5-8-17(14)27-18)20(25)13-11-15(23)21(16(24)12-13)26-10-9-22/h4-6,8,11-12H,2-3,7,9-10H2,1H3
96027-84-8Relevant articles and documents
Targeted SIRT3 agonist and application thereof in AML (acute myeloid leukemia) treatment drugs
-
Paragraph 0030; 0031; 0032, (2018/07/30)
The invention relates to a targeted SIRT3 agonist and application thereof in AML (acute myeloid leukemia) treatment drugs, which belong to the technical field of anti-hematologic tumor pharmacology. The technical problem which is solved by the invention is to provide a compound as the SIRT3 agonist. The compound includes the compound shown in the drawing or a pharmacologically acceptable salt thereof. The compound or the pharmacologically acceptable salt thereof disclosed by the invention can serve as the SIRT3 agonist, which has certain activity in resisting acute myeloid leukemia. The structural formula is shown in the description.
Pharmaceutical and veterinary compositions for the treatment of ischemic cardiac disorders
-
, (2008/06/13)
Pharmaceutical and veterinary compositions having as essential active ingredient at least one benzofuran derivative of the general formula: STR1 or a pharmaceutically acceptable acid addition salt thereof in which R represents an amino, monoethylamino or diethylamino radical and X1 and X2 represent hydrogen or iodine with the proviso that when R represents diethylamino X1 and X2 are different. These compositions are useful for the treatment of ischemic cardiac disorders.
